Cargando…
Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?
Glioblastoma (GBM) is the most malignant primary brain tumor without effective therapies. Since bevacizumab was FDA approved for targeting vascular endothelial growth factor receptor 2 (VEGFR2) in adult patients with recurrent GBM, targeted therapy against receptor tyrosine kinases (RTKs) has become...
Autores principales: | Qin, Anna, Musket, Anna, Musich, Phillip R, Schweitzer, John B, Xie, Qian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598918/ https://www.ncbi.nlm.nih.gov/pubmed/34806012 http://dx.doi.org/10.1093/noajnl/vdab133 |
Ejemplares similares
-
Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
por: Qin, Anna, et al.
Publicado: (2023) -
Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors
por: Montor, Wagner Ricardo, et al.
Publicado: (2018) -
Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme
por: Tilak, Manali, et al.
Publicado: (2021) -
The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer
por: Cerrato, Aniello, et al.
Publicado: (2018) -
Role of Receptor Tyrosine Kinases and Their Ligands in Glioblastoma
por: Carrasco-García, Estefanía, et al.
Publicado: (2014)